<font draggable="zu7Xt"></font><var lang="BAdg1d97"><style lang="5uLbf6rK"></style></var> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Clinical Trial
. 2012 Sep 10;30(26):3202-8.
doi: 10.1200/JCO.2012.42.0984. Epub 2012 Aug 6.

V体育平台登录 - Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

John Koreth  1 , Kristen E Stevenson, Haesook T Kim, Sean M McDonough, Bhavjot Bindra, Philippe Armand, Vincent T Ho, Corey Cutler, Bruce R Blazar, Joseph H Antin, Robert J Soiffer, Jerome Ritz, Edwin P Alyea 3rd
Affiliations
Clinical Trial

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

"VSports注册入口" John Koreth et al. J Clin Oncol. .

"V体育2025版" Abstract

Purpose: HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplantation (HSCT) is associated with increased graft-versus-host disease (GVHD) and impaired survival. In reduced-intensity conditioning (RIC), neither ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes. The proteasome inhibitor bortezomib has immunomodulatory properties potentially beneficial for control of GVHD in T-cell-replete HLA-mismatched transplantation VSports手机版. .

Patients and methods: We conducted a prospective phase I/II trial of a GVHD prophylaxis regimen of short-course bortezomib, administered once per day on days +1, +4, and +7 after peripheral blood stem-cell infusion plus standard tacrolimus and methotrexate in patients with hematologic malignancies undergoing MMUD RIC HSCT. We report outcomes for 45 study patients: 40 (89%) 1-locus and five (11%) 2-loci mismatches (HLA-A, -B, -C, -DRB1, or -DQB1), with a median of 36. 5 months (range, 17. 4 to 59 V体育安卓版. 6 months) follow-up. .

Results: The 180-day cumulative incidence of grade 2 to 4 acute GVHD was 22% (95% CI, 11% to 35%). One-year cumulative incidence of chronic GVHD was 29% (95% CI, 16% to 43%). Two-year cumulative incidences of nonrelapse mortality (NRM) and relapse were 11% (95% CI, 4% to 22%) and 38% (95% CI, 24% to 52%), respectively. Two-year progression-free survival and overall survival were 51% (95% CI, 36% to 64%) and 64% (95% CI, 49% to 76%), respectively. Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute and chronic GVHD, and survival similar to those of contemporaneous HLA-matched RIC HSCT at our institution V体育ios版. Immune recovery, including CD8(+) T-cell and natural killer cell reconstitution, was enhanced with bortezomib. .

Conclusion: A novel short-course, bortezomib-based GVHD regimen can abrogate the survival impairment of MMUD RIC HSCT, can enhance early immune reconstitution, and appears to be suitable for prospective randomized evaluation. VSports最新版本.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

"VSports app下载" Figures

Fig 1.
Fig 1.
Bortezomib–mismatched unrelated donor reduced-intensity conditioning hematopoietic stem-cell transplantation. (A) Sustained total donor chimerism at days 30, 100, and 180 after transplantation in patients initially engrafted and without evidence of disease relapse/progression. Triangles indicate patients without sustained donor engraftment (≥ 70% total donor cell chimerism). Of note, donor chimerism analysis was not mandated beyond day 100. (B) Cumulative incidence of nonrelapse mortality (NRM; with relapse/progression as a competing event) and relapse/progression (with death as a competing event). (C) Cumulative incidence of grade 2 to 4 acute graft-versus-host disease (aGVHD) and grade 3 to 4 aGVHD (with relapse/progression and death as competing events). (D) Cumulative incidence of chronic GVHD (cGVHD; with relapse/progression and death as competing events). (E) Overall and progression-free survival. (F) Overall survival for HLA-C mismatched and non–HLA-C mismatched transplantation.
Fig 2.
Fig 2.
Bortezomib–mismatched unrelated donor (MMUD) and sirolimus–matched unrelated donor (MUD) cohorts. (A) CD3+ total T-cell reconstitution; (B) CD8+ T-cell reconstitution; (C) CD4+ T-cell reconstitution; (D) natural killer cell reconstitution. Median cell counts (with vertical bars indicating interquartile range). (*) Significant P value.
See this image and copyright information in PMC

Comment in

References (V体育ios版)

    1. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–3219. - PMC - PubMed
    1. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–4583. - PubMed
    1. Petersdorf EW, Gooley T, Malkki M, et al. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007;69(suppl 1):25–30. - VSports注册入口 - PubMed
    1. Ho VT, Kim HT, Liney D, et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:845–850. - PubMed
    1. Nakamae H, Storer BE, Storb R, et al. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: A multicenter trial. Biol Blood Marrow Transplant. 2010;16:384–394. - VSports - PMC - PubMed

"V体育安卓版" MeSH terms